Collaborative Arrangements (Tables)

3 Months Ended

Mar. 31, 2014

Collaborative Arrangements

Schedule of net revenue from collaborative arrangements recognized

	Three Months Ended March 31,
(In thousands)	2014			2013
GSK	$	(780	)	$	1,322
Other	—			22
Net revenue from collaborative arrangements	$	(780	)	$	1,344

Schedule of revenue recognized from GSK under the LABA collaboration and strategic alliance agreements

	Three Months Ended March 31,
(In thousands)	2014			2013
Royalty revenue	$	730		$	—
Amortization of intangible assets	(1,780		)	—
Net royalty revenue	(1,050		)	—
LABA collaboration	—			907
Strategic alliance—MABA program license	270			415
Total net revenue from GSK	$	(780	)	$	1,322

Summary of reductions to R&D expenses related to the reimbursement payments

	Three Months Ended March 31,
(In thousands)	2014		2013
GSK	$	43	$	171
Merck	—		1,429
Alfa Wassermann	72		208
R-Pharm	18		326
Total reduction to R&D expense	$	133	$	2,134